Stearoyl-CoA Desaturase 1 (SCD-1 or EC188.8.131.52) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Stearoyl-CoA Desaturase 1 (SCD-1 or EC184.108.40.206) - Pipeline Review, H1 2016', provides in depth analysis on Stearoyl-CoA Desaturase 1 (SCD-1 or EC220.127.116.11) targeted pipeline therapeutics. The report provides comprehensive information on the Stearoyl-CoA Desaturase 1 (SCD-1 or EC18.104.22.168), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Stearoyl-CoA Desaturase 1 (SCD-1 or EC22.214.171.124) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Stearoyl-CoA Desaturase 1 (SCD-1 or EC126.96.36.199) - The report reviews Stearoyl-CoA Desaturase 1 (SCD-1 or EC188.8.131.52) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Stearoyl-CoA Desaturase 1 (SCD-1 or EC184.108.40.206) targeted therapeutics and enlists all their major and minor projects - The report assesses Stearoyl-CoA Desaturase 1 (SCD-1 or EC220.127.116.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Stearoyl-CoA Desaturase 1 (SCD-1 or EC18.104.22.168) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Stearoyl-CoA Desaturase 1 (SCD-1 or EC22.214.171.124) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Stearoyl-CoA Desaturase 1 (SCD-1 or EC126.96.36.199) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Stearoyl-CoA Desaturase 1 (SCD-1 or EC188.8.131.52) Overview 6 Therapeutics Development 7 Stearoyl-CoA Desaturase 1 (SCD-1 or EC184.108.40.206) - Products under Development by Stage of Development 7 Stearoyl-CoA Desaturase 1 (SCD-1 or EC220.127.116.11) - Products under Development by Therapy Area 8 Stearoyl-CoA Desaturase 1 (SCD-1 or EC18.104.22.168) - Products under Development by Indication 9 Stearoyl-CoA Desaturase 1 (SCD-1 or EC22.214.171.124) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Stearoyl-CoA Desaturase 1 (SCD-1 or EC126.96.36.199) - Products under Development by Companies 12 Stearoyl-CoA Desaturase 1 (SCD-1 or EC188.8.131.52) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Stearoyl-CoA Desaturase 1 (SCD-1 or EC184.108.40.206) - Companies Involved in Therapeutics Development 19 Daiichi Sankyo Company, Limited 19 Galmed Pharmaceuticals Ltd. 20 GlaxoSmithKline Plc 21 Johnson & Johnson 22 Novartis AG 23 Sanofi 24 Xenon Pharmaceuticals Inc. 25 Stearoyl-CoA Desaturase 1 (SCD-1 or EC220.127.116.11) - Drug Profiles 26 Aramchol - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 GSK-1940029 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 SAR-224 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Small Molecule to Inhibit SCD1 for Metabolic Disorders - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 XEN-801 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Stearoyl-CoA Desaturase 1 (SCD-1 or EC18.104.22.168) - Dormant Projects 37 Stearoyl-CoA Desaturase 1 (SCD-1 or EC22.214.171.124) - Discontinued Products 38 Stearoyl-CoA Desaturase 1 (SCD-1 or EC126.96.36.199) - Featured News & Press Releases 39 Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease 39 Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study 39 Feb 10, 2016: Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne 40 Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease 40 Sep 24, 2015: Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial 41 Aug 13, 2015: Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America 42 Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States 43 Jan 28, 2015: Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production 43 Dec 01, 2014: Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers 44 Nov 13, 2014: Galmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones 44 Sep 23, 2014: Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 45 Sep 02, 2014: Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events 45 Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 46 Jul 08, 2014: Galmed Announces Publication of Aramchol Phase IIa Trial in the Clinical Gastroenterology and Hepatology Journal 47 Jun 09, 2014: Galmed Pharmaceuticals Announces the Filing of a Provisional Patent Application for the Use of Aramchol for the Treatment of Lipodystrophy 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 18 Pipeline by Daiichi Sankyo Company, Limited, H1 2016 19 Pipeline by Galmed Pharmaceuticals Ltd., H1 2016 20 Pipeline by GlaxoSmithKline Plc, H1 2016 21 Pipeline by Johnson & Johnson, H1 2016 22 Pipeline by Novartis AG, H1 2016 23 Pipeline by Sanofi, H1 2016 24 Pipeline by Xenon Pharmaceuticals Inc., H1 2016 25 Dormant Projects, H1 2016 37 Discontinued Products, H1 2016 38
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.